Switzerland’s Sandoz sees Canada and Brazil markets as testing grounds before semaglutide goes off patent in Europe and the U.S. in the 2030s.
Source link
About The Author
Sandoz CEO Says Size of Weight-Loss Generics Market Is Unknown